A Phase 2 interventional study of Busulfan and Fludarabine in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Acute Leukemia, sponsored by Center for International Blood and Marrow Transplant Research. Active, not recruiting at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.
Sponsored by Center for International Blood and Marrow Transplant Research · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 7 open to participants now, 13 under way, 1 of them phase 3. Busulfan · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 5th largest by planned enrollment of the 71 interventional ones that give a count, is one of 2 that started in 2023, is one of 48 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 72nd registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →7 of the 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
Masonic Cancer Center, University of Minnesota · Sites in United States
Ages up to 60
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 4–65
Fred Hutchinson Cancer Center · Sites in United States
Ages 1–60
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Busulfan: first FDA approval 1954 (MYLERAN), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 56 · Phase 3 5
First in 1988; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 313 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 40 across the 71 interventional studies. Of the 55 that completed or were terminated, 32 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 73 have an industry lead sponsor. The 10 most frequent:
Center for International Blood and Marrow Transplant Research is the lead sponsor of 32 studies on the registry; 8 are open to participants now.
Center for International Blood and Marrow Transplant Research has 9 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
4 of the studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT04872595Memorial Sloan Kettering Cancer CenterA Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
| NCT05735717Masonic Cancer Center, University of MinnesotaMT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are:
Stratum 1 Recipient Inclusion Criteria:
One of the following diagnoses:
Stratum 2 Recipient Inclusion Criteria:
One of the following diagnoses:
Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with \< 5% blasts in the bone marrow.
Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
Stratum 3 Recipient Inclusion Criteria:
Donor Inclusion Criteria (note: donors are not research subjects):
Recipient Exclusion Criteria (Strata 1, 2, and 3):
Donor Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients Receive: Patients receive: Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3 Fludarabine (150 mg/m2 total dose) IV on days -6 to -2 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
Drug: Busulfan · Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes
Patients receive: Fludarabine (90 mg/m2 total dose) IV on days -7 to -5 Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes · Radiation: Total-body irradiation
Patients receive: Fludarabine (150-180 mg/m2 total dose) IV on days -6 to -2 Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
Drug: Busulfan · Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes
Patients receive: Fludarabine (125-150 mg/m2 total dose) IV on days -7 to -3 Melphalan (100-140 mg/m2) IV on day -1 Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes · Drug: Melphalan
Patients receive: Fludarabine (150mg/m2 total dose) IV on days -6 to -2 Cyclophosphamide (29-50mg/kg) IV on days -6 and -5 TBI (200cGy) on day -1 Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.
Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Mesna · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes · Radiation: Total-body irradiation · Drug: Cyclophosphamide
Given IV or PO pre-transplant as part of conditioning regimen
Also known as: Busulfex®
Given IV pre-transplant as part of conditioning regimen
Also known as: Fludara®
Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0
Also known as: PBSC HSCT, PBSC HCT, PBSC Transplantation, PBSCT
Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours. First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.
Also known as: Cytoxan®, PTCy
Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.
Also known as: Mesnex®
Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.
Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.
Also known as: MMF, Cellcept®
Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.
Also known as: PRO
Given IV pre transplant as part of conditioning regimen
Administered pre-transplant as part of conditioning regimen
Also known as: TBI
Given IV pre-transplant as part of conditioning regimen
Also known as: Cytoxan®
Infection Free Survival
Survival at 100 days without grades 2-3 infections (per BMT CTN grading criteria)
Time frame: 100 days post-HCT
Overall Survival
Defined as time interval between date of transplant and death from any cause
Time frame: 1-year post-HCT
Progression-free survival
Defined as disease relapse or progression, or death by any cause
Time frame: 1-year post-HCT
Infection-free survival
Defined as death and grades II-III infection (per BMT CTN criteria)
Time frame: 1-year post-HCT
Graft versus host disease relapse free survival
Defined as relapse or progression of underling disease (by 1 year), grade III-IV acute GvHD (by 6 months), chronic GvHD requiring systemic immune suppression (by 1 year), or death by any cause (by 1 year).
Time frame: 1-year post-HCT
Non-relapse mortality
Defined as death without evidence of disease progression or recurrence
Time frame: 1-year post-HCT
Cumulative incidence of neutrophil recovery
Defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/mm3 for three consecutive measurements on three different days
Time frame: Day 28 post-HCT
Cumulative incidence of platelet recovery
Defined as platelet count ≥20,000/mm\^3 or ≥50,000/mm\^3 with no platelet transfusions within seven days.
Time frame: Day 28 post-HCT
Cumulative incidence of primary and secondary graft failure
Primary graft failure is defined as no neutrophil recovery to ≥ 500 cells/mm3 by Day 28 post HCT. Secondary graft failure is defined as as initial neutrophil count recovery followed by subsequent decline in absolute neutrophil counts \<500 cells/mm3, unresponsive to growth factor therapy, but cannot be explained by infection, disease relapse, or medications.
Time frame: Day 28 and 1-year post-HCT
Donor T-Cell Chimerism
Defined as percent of donor chimerism via peripheral blood
Time frame: Day 28, 100 and 365 post-HCT
Cumulative incidence of acute GvHD
Defined as cumulative incidence of grades II-IV acute GvHD
Time frame: Day 100 and Day 180 post-HCT
Cumulative incidence of chronic GvHD
Time frame: 1-year post-HCT
Cumulative incidence of grade 2-3 bacterial, fungal, and viral infections
Defined as grades 2-3 infection as defined by BMT CTN grading criteria.
Time frame: Day 100 and 1-year post-HCT
Cumulative incidence of grades 2-3 BK virus hemorrhagic cystitis
Defined as incidence of BK virus hemorrhagic cystitis per BMT CTN grading criteria
Time frame: 1-year post-HCT
Cumulative incidence of relapse/progression
Defined as disease relapse or progression from Day 0 to 1-year post-HCT
Time frame: 1-year post-HCT
Overall Toxicity
To tabulate adverse events (AEs, experienced by recipients, defined as grade 3-5 unexpected and grade 5 expected AEs according to CTCAE v5
Time frame: 1-year post-HCT
Incidence and Severity of cytokine release syndrome
Defined and graded using the ASTCT grading criteria.
Time frame: within 14 days post-HCT
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 36 months is below that.
Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Busulfan · Melphalan · Cyclophosphamide
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Center for International Blood and Marrow Transplant Research